ADCYAP1 and Parkinson disease: PACAP inhibits pathological processes in Alzheimer’s disease (AD) and Parkinson’s disease (PD) models through PAC1-R [5], and thus, PAC1-R could be a target for the development of drugs for neurodegenerative diseases.